Toripalimab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Toripalimab |
| DrugBank ID | DB15043 |
| Brand Names (EU) | Loqtorzi |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 93.76% |
Approved Indication (EMA)
Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | mixed-type autoimmune hemolytic anemia | 93.76% | DL |
| 2 | idiopathic aplastic anemia | 93.76% | DL |
| 3 | dermatitis | 93.69% | DL |
| 4 | paroxysmal nocturnal hemoglobinuria | 93.67% | DL |
| 5 | drug-induced autoimmune hemolytic anemia | 93.67% | DL |
| 6 | proteinuria | 93.07% | DL |
| 7 | acne keloid | 93.05% | DL |
| 8 | neonatal autoimmune hemolytic anemia | 93.03% | DL |
| 9 | primary CD59 deficiency | 92.84% | DL |
| 10 | amyopathic dermatomyositis | 92.79% | DL |
| 11 | neonatal dermatomyositis | 92.74% | DL |
| 12 | cold agglutinin disease | 92.47% | DL |
| 13 | hydroa vacciniforme, familial | 92.41% | DL |
| 14 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | 92.36% | DL |
| 15 | acrodermatitis chronica atrophicans | 92.25% | DL |
| 16 | hepatic veno-occlusive disease-immunodeficiency syndrome | 91.69% | DL |
| 17 | pancytopenia due to IKZF1 mutations | 91.04% | DL |
| 18 | chromhidrosis | 90.97% | DL |
| 19 | adult idiopathic neutropenia | 90.78% | DL |
| 20 | congenital neutropenia-myelofibrosis-nephromegaly syndrome | 90.78% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.